Back to top

Research Daily

Tuesday, October 25, 2016

Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), General Mills (GIS) and Pfizer (PFE).

AT&T is in the headlines because of the Time Warner (TWX) deal, which will likely get plenty of regulatory scrutiny. The stock had lost ground prior to the deal announcement as the market's earlier affinity big dividend-paying telecom stocks had cooled off to some extent. That said, it is still up more than 7% year-to-date, doing better than both Verizon as well as the broader S&P 500 index. AT&T's Q3 results were mixed, though the strategic rationale for the Time Warner deal is compelling. (You can read the full research report on AT&T here>>)

General Mills shares have not been doing too well lately, likely reflecting weakness in the company's U.S. Retail segment as a result of lower demand amid changing consumer food preferences. But the analyst likes its robust restructuring savings, which are making up for the slower revenue growth. Though consumer-focused innovation and marketing drive as well as greater distribution of natural and organic portfolio helped improve the top line on many businesses in segments like cereals and snacks in fiscal 2016, a material improvement may take time. (You can read the full research report on General Mills here>>)

Pfizer shares have lagged the market this year, in line with the broader the pharmaceutical space, on concerns about the group's pricing power in the current political environment. These issues notwithstanding, the analyst likes Pfizer’s strategy of strengthening its product portfolio and pipeline through acquisitions and licensing deals. The 2015 Hospira acquisition has significantly expanded Pfizer's sterile injectable and biosimilar capabilities. However, headwinds remain in the form of genericization and the expiration of a few co-promotion agreements which will continue to hamper top-line growth. Estimate movement has been mixed lately ahead of the company’s Q3 earnings release. (You can read the full research report on Pfizer here>>)

Other noteworthy reports we are featuring today include T-Mobile (TMUS), United Continental (UAL), and AvalonBay Communities (AVB).  

You can find all of today's stock research reports here>>

Confidential: Best Trades from Zacks Research
Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand.  Click for his prized selections right now >>

Sheraz Mian

Director of Research

Note: If you want an email notification each time Sheraz publishes a new article, please click here >>

Featured Reports

Weak 4Q Ahead for Sonoco (SON)

The Zacks analyst believes that while a stronger dollar, fewer business days will hurt fourth-quarter results, Sonoco's overall performance in 2016 will improve y-o-y.

New Upgrades

New Downgrades